linagliptine 5 mg; linagliptine 5 mg and pioglitazone 30 mg
Проводит Boehringer Ingelheim
Страница компанииA 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 1356 (5 mg) as Monotherapy or in Combination With Other Antidiabetic Medications in Type 2 Diabetic Patients.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00736099/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–82 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 2122 чел. во всех странах исследования.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 2 · невключение: 7
Критерии включения
- Signed and dated written informed consent in accordance with the GCP and local legislation.
- Patients completing the entire treatment period as a double blind trial whether or not they have been treated with rescue medication.
Критерии невключения
- Patients who meet one or more of the withdrawal criteria of the treatment period of the previous trial.
- Pre-menopausal women (last menstruation =< 1 year prior to signing informed consent) who:
- are nursing or pregnant,
- or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of birth control) and vasectomised partners. No exception will be made.
- Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation.
- Drug abuse which, in the opinion of the investigator, would interfere with trial participation.
- Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication.
Источник: ClinicalTrials.gov, NCT00736099 · запись обновлена в реестре 27 июня 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 17
- Frequency of Patients With Adverse Events (AEs) — 78 weeks
- Frequency of Patients With Investigator-defined Hypoglycaemic Adverse Events — 78 weeks
- Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ) — 78 weeks
- Frequency of Patients With Adjudication of Cardiac and Cerebrovascular Events — 78 weeks
- Number of Patients With Abnormalities in Vital Signs — 78 weeks
- Number of Patients With Abnormalities in Haematology: Eosinophils — 78 weeks
- Number of Patients With Abnormalities in Haematology: Haemoglobin — 78 weeks
- Number of Patients With Abnormalities in Haematology: Haematocrit — 78 weeks
- Number of Patients With Abnormalities in Haematology: Red Blood Cell Count — 78 weeks
- Number of Patients With Abnormalities in Haematology: White Blood Cell Count — 78 weeks
Цель исследования
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
The treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00736099 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.